Dr. Stanley Plotkin, a vaccine expert and a former pharmaceutical executive, this week told SVB Leerink analysts that achieving between 60% and 70% protection should aid “long-term containment of the pandemic,” though he doesn’t expect the first generation of COVID-19 vaccines to achieve those efficacy levels.